Le Fonds mondial approuve le financement de deux subventions nationales, une subvention multipays et 10 demandes de fonds de contrepartie
Global Fund Board approves funding for two country grants, a multi-country grant and 10 matching funds requests
The Kenya Red Cross Society (KRCS) has been a successful principal recipient (PR) for an HIV grant (KEN-H-KRCS) entitled “The road towards an HIV free society” based on the ratings of the grant over the years.
Small-scale fraud found in training activities and meetings related to a Global Fund TB grant to Kenya
An investigation by the Office of the Inspector General (OIG) into a TB grant to Kenya has identified $62,557 in non-compliant expenditures. A report on the investigation was released on 9 February 2017.
Le CTEP loue la demande de financement TB/VIH du Kenya au Fonds mondial pour l’attention portée aux populations clés et aux droits de l’homme
TRP praises Kenya's TB/HIV funding request to the Global Fund for its sensitivity to key populations and human rights
Les cibles nationales ambitieuses de mise sous traitement ne se retrouvent souvent pas dans les cadres de résultats des subventions, selon le CAS
Ambitious national targets for getting people on treatment often not reflected in grant performance frameworks, GAC says
In its report to the Board on the third batch of grants it recommended for approval, the Grant Approvals Committee (GAC) said that it was very concerned that national programs have ambitious goals to continue scaling up antiretroviral therapy (ART), with the aim of achieving the 90-90-90 targets or even treating all patients diagnosed with HIV – but that these goals are not necessarily reflected in performance frameworks because of “limitation
Dans ce qui a été salué comme une « percée » et susceptible de « changer la donne », la Fondation Bill et Melinda Gates et deux fabricants de médicaments génériques ont conclu un accord de prix qui entraînera des économies significatives au niveau des coûts des antirétroviraux.
In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.